Cefixime
From Wikipedia, the free encyclopedia
Cefixime
|
|
Systematic (IUPAC) name | |
(6R,7R)-7-{[2-(2-amino-1,3-thiazol-4-yl)-2-(carboxy methoxyimino)acetyl]amino}-3-ethenyl-8-oxo-5-thia- 1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
|
Identifiers | |
CAS number | |
ATC code | J01 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C16H15N5O7S2 |
Mol. mass | 453.452 g/mol |
Pharmacokinetic data | |
Bioavailability | 40% to 50% |
Protein binding | Approximately 60% |
Metabolism | ? |
Half life | Variable Average 3 to 4 hours |
Excretion | Renal and biliary |
Therapeutic considerations | |
Pregnancy cat. |
B |
Legal status | |
Routes | Oral |
Cefixime is an oral third generation cephalosporin antibiotic. It was sold under the trade name Suprax in the USA, until 2003 when it was taken off the market by drug manufacturer Wyeth after its patent expired. The oral suspension form of "Suprax" was re-launched by Lupin in the USA. Cefixime is still available in Canada. It is used to treat gonorrhea[1], tonsilitis[2], and pharyngitis[2].
[edit] References
- ^ McMillan A, Young H. (2007). "The treatment of pharyngeal gonorrhoea with a single oral dose of cefixime.". Int J STD AIDS 18 (4): 253-4. doi: . PMID 17509176.
- ^ a b Adam D, Hostalek U, Tröster K. (1995). "5-day cefixime therapy for bacterial pharyngitis and/or tonsillitis: comparison with 10-day penicillin V therapy.". Infection 23 (Suppl 2): S83-6. doi: . PMID 8537138.
[edit] External links
- Suprax Online - Information about cefixime.
- Notice to Readers: Discontinuation of Cefixime Tablets --- United States - A FDA report alerting physicians about the discontinuation of cefixime.
|